Willems L - Search Results

1

Selecting an appropriate and reimbursed anti-osteoporotic treatment option: a practical tool in the Belgian setting.

Grootaert V, De Keulenaer J, Boonen S, Sermon A, Spriet I, Willems L. Grootaert V, et al. Among authors: willems l. Acta Clin Belg. 2012 Jan-Feb;67(1):13-8. doi: 10.2143/ACB.67.1.2062620. Acta Clin Belg. 2012. PMID: 22480033

2

Stimulation of the i.v. to oral switch of bioavailable drugs by phone calls in a Belgian tertiary care hospital.

Vanstraelen K, Verhaegen J, Peetermans WE, Willems L, Spriet I. Vanstraelen K, et al. Among authors: willems l. Acta Clin Belg. 2013 May-Jun;68(3):179-82. doi: 10.2143/ACB.3212. Acta Clin Belg. 2013. PMID: 24156216

3

Drug-related admissions due to interaction with an old drug, lithium.

De Winter S, Meersseman W, Verelst S, Willems L, Spriet I. De Winter S, et al. Among authors: willems l. Acta Clin Belg. 2013 Sep-Oct;68(5):356-8. doi: 10.2143/ACB.3347. Acta Clin Belg. 2013. PMID: 24579242

4

Development of clinical pharmacy in Belgian hospitals through pilot projects funded by the government.

Somers A, Spinewine A, Spriet I, Steurbaut S, Tulkens P, Hecq JD, Willems L, Robays H, Dhoore M, Yaras H, Vanden Bremt I, Haelterman M. Somers A, et al. Among authors: willems l. Acta Clin Belg. 2019 Apr;74(2):75-81. doi: 10.1080/17843286.2018.1462877. Epub 2018 Apr 30. Acta Clin Belg. 2019. PMID: 29708056

5

Augmented renal clearance in the critically ill: how to assess kidney function.

Grootaert V, Willems L, Debaveye Y, Meyfroidt G, Spriet I. Grootaert V, et al. Among authors: willems l. Ann Pharmacother. 2012 Jul-Aug;46(7-8):952-9. doi: 10.1345/aph.1Q708. Epub 2012 Jun 12. Ann Pharmacother. 2012. PMID: 22693271

6

Evaluation of drotrecogin alpha use in a Belgian university hospital.

Spriet I, Meersseman W, Wilmer A, Meyfroidt G, Casteels M, Willems L. Spriet I, et al. Among authors: willems l. Pharm World Sci. 2006 Oct;28(5):290-5. doi: 10.1007/s11096-006-9045-3. Epub 2006 Nov 17. Pharm World Sci. 2006. PMID: 17111246

7

Therapeutic drug monitoring of phenytoin in critically ill patients.

von Winckelmann SL, Spriet I, Willems L. von Winckelmann SL, et al. Among authors: willems l. Pharmacotherapy. 2008 Nov;28(11):1391-400. doi: 10.1592/phco.28.11.1391. Pharmacotherapy. 2008. PMID: 18956999 Review.

8

Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis.

Spriet I, Meersseman W, Annaert P, de Hoon J, Willems L. Spriet I, et al. Among authors: willems l. Eur J Clin Pharmacol. 2011 Jul;67(7):753-5. doi: 10.1007/s00228-011-1066-8. Epub 2011 Jun 3. Eur J Clin Pharmacol. 2011. PMID: 21638033 No abstract available.

9

The impact of a transjugular intrahepatic portosystemic shunt on the pharmacokinetics of caspofungin in a critically ill patient.

Spriet I, Meyfroidt G, Maleux G, Verslype C, Willems L. Spriet I, et al. Among authors: willems l. Pharmacology. 2012;90(5-6):247-50. doi: 10.1159/000342906. Epub 2012 Sep 20. Pharmacology. 2012. PMID: 23007631

10

No interference of the 1,3-β-D-glucan containing nutritional supplement ImunixX with the 1,3-β-D-glucan serum test.

Spriet I, Desmet S, Willems L, Lagrou K. Spriet I, et al. Among authors: willems l. Mycoses. 2011 Sep;54(5):e352-3. doi: 10.1111/j.1439-0507.2010.01922.x. Epub 2010 Jul 19. Mycoses. 2011. PMID: 20637053

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

613 results

Search Page

Filters